Slayback’s ‘Thoughtful’ Generics Play Nets $60m KKR Investment

Niche plays continue to attract deal interest, with the global investment firm KKR pumping in $60m in the complex generic and specialty products firm Slayback Pharma, headed by a former executive of India’s Dr Reddy’s Laboratories.